Institution · Notable Labs (United States)

Most cited papers from Notable Labs (United States)

Notable Labs (United States)

What are the most cited papers from Notable Labs (United States)?

The most cited paper from Notable Labs (United States) is "Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia" (Geoffrey L. Uy et al., 2020), with 332 citations. Next come "Analyzing security costs" (109) and "Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study" (78).

Published TypeFieldAccess

Showing 28 of 28 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia Geoffrey L. Uy et al. · Blood Open access	15 Sep 2020	332
2	Analyzing security costs Rebecca T. Mercuri · Communications of the ACM	Jun 2003	109
3	Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study Jenny L. Smith et al. · Clinical Cancer Research Open access	12 Nov 2019	78
4	Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms Michael Alexander Spinner, Alexey A. Aleshin, Marianne T. Santaguida et al. · Blood Advances Open access	22 Jun 2020	42
5	Scoping identity theft Rebecca T. Mercuri · Communications of the ACM	May 2006	38
6	On auditing audit trails Rebecca T. Mercuri · Communications of the ACM	2003	26
7	Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression Philip Vitorino, Chen-Hua Chuang, Alexandre Iannello et al. · Translational Oncology Open access	15 Oct 2020	25
8	Challenges in forensic computing Rebecca T. Mercuri · Communications of the ACM	Dec 2005	22
9	An educational venture into 3D Printing Rebecca T. Mercuri, Kevin Meredith Conference paper	Mar 2014	21
10	Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia Arthur A. Branstrom, Liangxian Cao, Bansri Furia et al. · Frontiers in Oncology Open access	9 Feb 2022	14
11	Criminal Defense Challenges in Computer Forensics Rebecca T. Mercuri · Lecture notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering Conference paper	2010	13
12	Computer security Rebecca T. Mercuri · Communications of the ACM	Oct 2002	12
13	Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML Debbie C. Strachan, Christine J. Gu, Ryosuke Kita et al. · Cancers Open access	18 Dec 2022	11
14	Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion–associated myeloid neoplasm Oriana Miltiadous et al. · Blood Advances Open access	22 Sep 2021	8
15	Courtroom Considerations in Digital Image Forensics Rebecca T. Mercuri Book chapter	30 Jul 2012	6
16	Ex vivo discovery of synergistic drug combinations for hematologic malignancies Kamran A. Ali, Reecha D. Shah, Anukriti Dhar et al. · SLAS DISCOVERY Open access	13 Dec 2023	4
17	Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay Elliot Stieglitz, Christine J. Gu, Michelle Richardson et al. · JCO Precision Oncology Open access	Sep 2023	4
18	The risks of election believability (or lack thereof) Rebecca T. Mercuri, Peter G. Neumann · Communications of the ACM	24 May 2021	4
19	Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples Sacha Prashad, Leylah M. Drusbosky, Hassan Abdulmaoula Sibai et al. · Blood	2 Dec 2016	4
20	From Surviving to Thriving: A Qualitative Study of Adapting Telehealth Systems for Specialty Diabetes Care Across Four California Medical Centers Sarah C. Haynes, Miriam Sarkisian, Aaron Barak Neinstein et al. · Clinical Diabetes Open access	17 Apr 2024	3
21	Revival of the PLK1 Inhibitor Volasertib in Relapsed/Refractory Acute Myeloid Leukemia Glenn C. Michelson, Scott Houston, Christopher Ross Leonardi et al. · Clinical Lymphoma Myeloma & Leukemia	26 Aug 2024	1
22	Open Software and Hardware Blood Glucose Analysis as a STEM Project Saamia Khan, Yashwee Kothari, Max Ramer et al. Conference paper	Mar 2019	1
23	Yo'City: Personalized and Boundless 3D Realistic City Scene Generation via Self-Critic Expansion Lu, Keyang, Zhou, Sifan, Xu, Hongbin et al. · arXiv (Cornell University) PreprintOpen access	24 Nov 2025	0
24	P998: TRETINOIN AND CALCITRIOL ENHANCE TREATMENT REGIMENS FOR JUVENILE MYELOMONOCYTIC LEUKEMIA IN EX VIVO DRUG SENSITIVITY ASSAYS Elliot Stieglitz, Christine J. Gu, Anukriti Dhar et al. · HemaSphere Open access	Aug 2023	0
25	An Observational Study to Collect and Assess Tissue Samples from Subjects with One of Three Neoplastic Conditions (ANSWer) Susanna Wen, Michelle Richardson, Ryo Kita et al. · Blood	4 Nov 2020	0
26	Correlating Clinical and Genomic Features with Ex Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms Michael Alexander Spinner, Steven A. Schaffert, Alexey A. Aleshin et al. · Blood	5 Nov 2020	0
27	Identification of AML/MDS Drug Sensitization By In Vivo Chemotherapy Administration John Sutton Welch, Lakshmi Ramya Chelapareddy, Michelle Richardson et al. · Blood	4 Nov 2020	0
28	Forensics in the COMPSCI classroom: keynote address Rebecca T. Mercuri · Journal of computing sciences in colleges	May 2010	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.